Jul. 17 at 4:59 PM
$XERS When you have drugs as Recorlev that is likely on the way to Korlym bumbers and grossing 85%(and beside of it wide range of drugs and tech that already generaring hundreds of millions including Gvoke), the likelihood to see during next few/several months double digits and during 2026, ~20-30$ P/S (and growing from there) is very high. Especially when Xeris should reach soon
$300M revenue (which is already nearby half of Corcept revenue) and of course, profitablity is very near as well. Xeris is already -0.06$. Fair to think we can see a beginning of positive eps era already Q3 and if not, very likely Q4. While entire 2026 should be profitable & growing profits QoQ, especially based on Recorlev growth, but Gvoke as well of course... and we won't say no to any potential Tech deal...
Xeris has everything & growing fast & i like it
Yes, i can see Gimmicks going up/down... but give me rapid&stable growth,
$650-700M Rev, 0.2-0.3$ eps/Q & ~70
$P/s till ~2029 and I'm satisfied.
